文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

类风湿关节炎相关间质性肺疾病的肺功能轨迹。

Lung function trajectory of rheumatoid arthritis-associated interstitial lung disease.

机构信息

Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Republic of Korea.

Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University Hospital, Cheonan, Republic of Korea.

出版信息

Rheumatology (Oxford). 2023 Sep 1;62(9):3014-3024. doi: 10.1093/rheumatology/kead027.


DOI:10.1093/rheumatology/kead027
PMID:36702465
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10473227/
Abstract

OBJECTIVES: To explore the course of lung function and RA disease activity and predictive factors for deteriorating lung function in patients with RA-interstitial lung disease (ILD). METHODS: The Korean Rheumatoid Arthritis-Interstitial Lung Disease cohort is a multicentre, prospective observational cohort. Patients with RA-ILD were enrolled and followed up annually for 3 years for RA disease activity and ILD status assessment. Group-based modelling was used to cluster a similar predicted percentage of forced vital capacity (FVC%) patterns into trajectories. RESULTS: This study included 140 patients who underwent at least two pulmonary function tests. Four distinctive trajectories for predicted FVC% were 'improving' [n = 11 (7.9%)], 'stable' [n = 68 (38.4%)], 'slowly declining' [n = 54 (48.6%)] and 'rapidly declining' [n = 7 (5.0%)]. Most (77.7%) patients maintained or improved to low RA disease activity. The lung function trajectory was not comparable to the RA disease activity trajectory. Age ≥70 years [relative risk (RR) 10.8 (95% CI 1.30, 89.71)] and early RA diagnosed within the preceding 2 years [RR 10.1 (95% CI 1.22, 84.2)] were associated with increased risk for rapidly declining predicted FVC%. The risk for deterioration or mortality increased in patients with a simultaneous diagnosis of RA and ILD within 24 weeks [RR 9.18 (95% CI 2.05, 41.0)] and the extent of lung involvement [RR 3.28 (95% CI 1.12, 9.60)]. CONCLUSION: Most patients with RA-ILD experienced stable or slowly declining lung function. In 5% of patients, predicted FVC% deteriorated rapidly, especially in older adults with early RA. The lung function trajectory was not comparable to the RA disease activity trajectory.

摘要

目的:探讨类风湿关节炎-间质性肺疾病(RA-ILD)患者肺功能的变化过程、RA 疾病活动度及肺功能恶化的预测因素。

方法:韩国类风湿关节炎-间质性肺疾病队列是一项多中心、前瞻性观察性队列研究。共纳入了 RA-ILD 患者,并在 3 年内每年对其 RA 疾病活动度和 ILD 情况进行评估。采用基于群组的模型将相似的用力肺活量(FVC)%预计值模式聚类为轨迹。

结果:本研究纳入了至少接受两次肺功能检查的 140 名患者。预测 FVC%有 4 种不同的轨迹:“改善”[n=11(7.9%)]、“稳定”[n=68(38.4%)]、“缓慢下降”[n=54(48.6%)]和“快速下降”[n=7(5.0%)]。大多数(77.7%)患者的 RA 疾病活动度保持在低水平或得到改善。肺功能轨迹与 RA 疾病活动度轨迹不相关。年龄≥70 岁[相对风险(RR)10.8(95%CI 1.30,89.71)]和发病 2 年内的早期 RA[RR 10.1(95%CI 1.22,84.2)]与快速下降的预测 FVC%风险增加相关。同时在 24 周内诊断为 RA 和 ILD[RR 9.18(95%CI 2.05,41.0)]以及肺受累程度[RR 3.28(95%CI 1.12,9.60)]的患者发生恶化或死亡的风险增加。

结论:大多数 RA-ILD 患者的肺功能稳定或缓慢下降。5%的患者预测 FVC%迅速恶化,尤其是发病年龄较大、发病时间较短的老年患者。肺功能轨迹与 RA 疾病活动度轨迹不相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d9/10473227/b51e62f5bf47/kead027f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d9/10473227/0242d179d54b/kead027f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d9/10473227/3ed007b49db0/kead027f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d9/10473227/b51e62f5bf47/kead027f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d9/10473227/0242d179d54b/kead027f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d9/10473227/3ed007b49db0/kead027f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d9/10473227/b51e62f5bf47/kead027f2.jpg

相似文献

[1]
Lung function trajectory of rheumatoid arthritis-associated interstitial lung disease.

Rheumatology (Oxford). 2023-9-1

[2]
Forced vital capacity trajectories and risk of lung transplant and ILD-related mortality among patients with rheumatoid arthritis-associated interstitial lung disease.

Clin Rheumatol. 2024-8

[3]
Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory.

Chest. 2023-4

[4]
Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model.

Respir Res. 2022-3-11

[5]
Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Arthritis Rheumatol. 2017-3

[6]
Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.

Respir Res. 2021-10-11

[7]
The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease.

Rheumatology (Oxford). 2022-11-28

[8]
Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.

Rheumatology (Oxford). 2017-8-1

[9]
Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study.

Intern Med J. 2020-9

[10]
A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease.

Clin Rheumatol. 2020-5

引用本文的文献

[1]
Association between impaired lung function and risk of spondyloarthritis: a cross-sectional study in the UK Biobank.

Ther Adv Musculoskelet Dis. 2025-9-1

[2]
The potential of semi-quantitative and quantitative methods in predicting progression in rheumatoid arthritis-associated interstitial lung disease.

Clin Rheumatol. 2025-6

[3]
Impact of csDMARDs vs. b/tsDMARDs on the Prognosis of Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multicenter, Retrospective Study.

Diagnostics (Basel). 2025-3-21

[4]
Mortality and Predictive Factors for Death Following the Diagnosis of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Retrospective, Long-Term Follow-Up Study.

J Clin Med. 2025-2-19

[5]
Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort study.

Lancet Rheumatol. 2025-3

[6]
Pulmonary involvement in newly diagnosed and untreated rheumatoid arthritis and psoriatic arthritis: a prospective longitudinal study.

Rheumatol Int. 2024-12-18

[7]
Long-term functional course of Sjögren's disease-associated interstitial lung disease.

ERJ Open Res. 2024-10-28

[8]
Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis.

BMC Pulm Med. 2024-9-27

[9]
A Systematic Review of the Key Predictors of Progression and Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Diagnostics (Basel). 2024-8-28

[10]
Clinical Course of Interstitial Lung Disease in Patients With Rheumatoid Arthritis.

ACR Open Rheumatol. 2024-12

本文引用的文献

[1]
Predictors of progression in rheumatoid arthritis-associated interstitial lung disease: A single-center retrospective study from China.

Int J Rheum Dis. 2022-7

[2]
The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease.

Rheumatology (Oxford). 2022-11-28

[3]
Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Population-Based Cohort.

Arthritis Care Res (Hoboken). 2022-12

[4]
Serum anti-citrullinated protein antibodies and rheumatoid factor increase the risk of rheumatoid arthritis-related interstitial lung disease: a meta-analysis.

Clin Rheumatol. 2021-11

[5]
Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management.

Eur Respir Rev. 2021-6-30

[6]
Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody.

BMJ Open. 2021-3-31

[7]
Corticosteroid responsiveness in patients with acute exacerbation of interstitial lung disease admitted to the emergency department.

Sci Rep. 2021-3-11

[8]
Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients.

Rheumatology (Oxford). 2021-8-2

[9]
Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis.

Rheumatology (Oxford). 2021-5-14

[10]
Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-associated Interstitial Lung Disease.

J Rheumatol. 2021-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索